Introduction
Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) patients (1). Hypertension is a major risk factor for cardiovascular disease and is highly prevalent in ESRD patients, although hypertension, unlike in the general population, is not always linearly associated with adverse outcomes (2) .
Recently, blood pressure (BP) variability has been found to be more closely associated with adverse outcomes in patients with vascular disease than that of 'usual' BP (3) and may play a causal role in the progression of organ damage and in triggering a vascular event (4, 5) . Some studies demonstrated that visit-tovisit BP variability was a novel risk factor for stroke (3) , cardiovascular events (3) , and all-cause mortality in the general population (6) . It is reported that visit-to-visit BP variability also predicted cardiovascular events and allcause mortality in patients with chronic kidney disease (7, 8) and hemodialysis (5, (9) (10) (11) (12) (13) (14) . Note, however, that different dialysis modalities should have different effects on BP due to the intermittent nature of hemodialysis and continuous nature of peritoneal dialysis (PD). To date, only a few studies have focused on BP variation and outcome in PD patients (15) (16) (17) .
There are many studies indicating that residual renal function (RRF) is a powerful predictor of morbidity and mortality in PD patients (18) (19) (20) . Yokota et al. reported that visit-to-visit BP variability was associated with renal function decline in nondiabetic chronic kidney disease (21) . Therefore, the aim of the present study was to investigate the relationships between visit-to-visit BP variability, RRF, and cardiovascular status in continuous ambulatory PD (CAPD) patients.
Materials and methods

Patients
We performed an observational study in prevalent PD patients in the PD Center of Peking University Third Hospital, People's Republic of China between 1 February 2006 and 31 January 2007. All PD patients aged 18 years and older, and who had been on CAPD therapy for at least 3 months in our PD center were eligible for participating in this study. The patients were clinically stable and visited our clinic regularly with BP measurements at each clinical visit. None of patients had atrial fibrillation. Patients that suffered an acute cardiovascular event [stroke, transient ischemic attack, myocardial infarction, angina, or heart failure (NYHA class III to IV)] prior to the study were not included. Patients that died during the observation period were excluded from the present analysis. All demographic data were obtained through patient chart review.
All patients received repeated BP measurements during the 1-year observation. Patients were evaluated for clinical and biochemical data, dialysis adequacy at baseline and at the end of 1-year observation. Measurements were performed during a scheduled visit. The first measurement, at least 3 months after the initiation of dialysis between 1 February 2006 and 31 January 2007 was taken as baseline. Echocardiographic evaluation and measurement of pulse wave velocity were done at the end of the 1-year observation.
The ethical committee of Peking University approved the study protocol and informed consent was obtained from each patient.
Dialysis therapy
PD patients were treated by 3-4 exchanges per day, using standard glucose-based dialysate solutions (Baxter China Ltd., Guangzhou, China).
Blood pressure measurements
BP measurements were performed during a scheduled monthly visit. BP was measured in a supine position after a 15-min rest using a mercury sphygmomanometer with a cuff of appropriate size. Phases I and V of the Korotkoff sound were taken as systolic BP (SBP) and diastolic BP (DBP), respectively. Three consecutive measurements were performed in every patient and the arithmetic mean of these measurements was used. Pulse pressure (PP) was calculated as SBP minus DBP.
Visit-to-visit systolic BP variability (VTV-SBPV) was defined as the standard deviation (SD) of all SBP values recorded during the baseline visit and the following visits during the study period. The SD of at least 5 visits' BP readings was used for the analyses in each patient (22) . Patients were then divided into HBPV (higher BP variability) group and LBPV (lower BP variability) group, according to the mean BP variation (23).
Blood biochemistry and dialysis adequacy
Fasting venous blood samples were taken from all study participants for evaluation of biochemical parameters. Biochemical parameters such as hemoglobin, urea, creatinine, serum glucose, triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, serum sodium, serum calcium, and phosphate were analyzed by standard procedures. Serum albumin was measured using the bromocresol green method. Intact parathyroid hormone (PTH) levels and sensitive C-reactive protein (SCRP) were determined using a commercial enzyme linked immunosorbent assay. Dialysis adequacy was assessed by urea clearance, Kt/V (K, clearance; t, treatment time; V, volume of urea distribution) (24) . Peritoneal Kt/V and renal Kt/V were measured separately; total Kt/V was the sum of peritoneal Kt/V and renal Kt/V. Urea distribution volume was calculated according to Watson's formula (25) . Renal Kt/V was used as an indicator of RRF.
Echocardiography
Echocardiograms were examined using an ultrasound machine (Sonoline G50 ultrasound system, Siemens Medical Solutions Inc. ). Left ventricular ejection fraction (LVEF) was determined by Simpson's method.
Measurement of pulse wave velocity (PWV)
Aortic PWV was measured by an automatic device, the Complior (Colson SG, Garges les Gonesses, France) (29) . Common carotid artery and femoral artery pressure wave forms were first noninvasively recorded using a TY-306 Fukuda pressure sensitive transducer (Fukuda Ltd., Tokyo, Japan). Measurements were performed consecutively over 10 cardiac cycles, and the mean value of these measurements was used. The distance traveled by the pulse wave (D) was measured over the body surface as the distance between the two recording sites, while pulse transit time (t) was automatically determined by the Complior. PWV was calculated as PWV = D/t. Details, as well as validation of this automatic method and its reproducibility, have been reported previously (29) . All PWV measurements were performed by the same skilled observer.
Statistical analysis
Continuous variables were expressed as mean ± SD or median (range), while categorical variables were expressed as ratio or percentage. One-sample Kolmogorov-Smirnov test was used to determine normality of distributions of continuous variables. Paired-samples t test or independentsamples t test were used, as appropriate, to compare differences for continuous variables. When the variables were not normally distributed, the Mann-Whitney U test or the Wilcoxon test were used. Comparison of categorical variables was performed using the chi-square test. A twotailed P-value less than 0.05 was considered significant.
Results
Baseline characteristics of the patients
There were 70 patients recruited for the final analysis. The demographic data of these 70 patients are shown in Table  1 . The mean age of the patients was 59.9 ± 13.3 years with a range of 26 to 85 years; the proportion of males was 40.0%. The patients had been on PD for 20.1 ± 23.0 (3.2-99.0) months when the study started. The etiologies of uremia included chronic glomerulonephritis in 20 patients, diabetes mellitus in 13 patients, hypertensive nephropathy in 11 patients, tubulointerstitial nephritis in 19 patients, polycystic kidney disease in 3 patients, obstructive nephropathy in 1 patient, and unknown etiology in 3 patients. Fifty-nine patients were on antihypertensive therapy; 65.7% had calcium-channel blockers, 44.3% angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARBs), 55.7% β-blockers, 10.0% diuretics, and 10.0% other. The average SD of the SBP was 14.82 ± 6.28 mmHg.
Comparisons at baseline between the two groups
The participants were divided into two groups according to the average SD of SBP (14.82): higher BP variability group (HBPV group) and lower BP variability group (LBPV group) ( Table 2) . Patients with higher VTV-SBPV had a higher SBP as compared to patients with lower VTV-SBPV (P < 0.05). There were no significant differences in age, prevalence of diabetes mellitus, time on dialysis, or biochemical results between the two groups. Table 3 showed longitudinal changes in selected study variables. In the LBPV group, renal Kt/V did not decrease significantly during the observation period, nor did ultrafiltration volume. However, peritoneal Kt/V increased (P < 0.05) and urine volume decreased (P < 0.01) significantly during the observation period.
Intragroup and intergroup comparisons
In the HBPV group, renal Kt/V decreased from 0.50 ± 0.49 to 0.32 ± 0.35 (P < 0.01), and peritoneal Kt/V increased Note: P 1 -value referred to comparison between the two groups at baseline; P 2 -value referred to comparison between the two groups at the end of follow-up. from 1.35 ± 0.51 to 1.54 ± 0.44 (P < 0.01). Urine volume was also significantly decreased (P < 0.01). However, there were no significant changes in ultrafiltration volume.
Patients with higher VTV-SBPV showed a decreased renal Kt/V compared to those with lower VTV-SBPV at the end of follow-up (P < 0.05). 3.4. Comparisons of cardiac structure and function between the two groups at the end of follow-up Patients' IVSDT, LVPWDT, LVMI, prevalence of LVH, and PWV were significantly higher in the HBPV group than those in the LBPV group (P < 0.01) ( Table 4 ).
Discussion
In the present study, we found that renal Kt/V obviously decreased in the HBPV group at the end of follow-up, whereas it did not differ in the LBPV group. Patients with higher VTV-SBPV showed a decreased renal Kt/V than those with lower VTV-SBPV, indicating a possible association of BP variability with RRF in PD patients.
Some previous studies suggest that RRF could predict mortality in ESRD patients (18) (19) (20) . Rocco et al. found from a multicenter prospective cohort study of 1446 prevalent PD patients that for each 10 L/week/1.73 m 2 increase in renal CrCl there was a 40% reduced risk of death, and that for each increase in weekly renal Kt/V of 0.1 there was a 12% reduction in the risk of death (19) . The ADEMEX study reported that each increase of 0.1 in renal Kt/V was associated with a 6% decrease in mortality (20) . Thus, considerable efforts have been put into finding ways to prevent the loss of RRF in PD patients.
Recently, BP variability is thought to be a parameter reflecting cardiovascular outcome (14, 30) . It can be quantified over both the short-term, using 24-h ambulatory BP measurements, and long-term variability using visit-to-visit BP readings. The SD of BP is a measure of the mean absolute distance between the observed measurements and their mean. It is often used in many studies and can reflect BP fluctuation (7, 14) . Thus, SD of SBP was adopted in our study. The association of BP variability with RRF in our study encourages us to seek new ways to help this patient population. In fact, Yokota et al. reported that VTV-BPV was associated with renal function decline in nondiabetic chronic kidney disease (21), but not in diabetic chronic kidney disease (31). Okada et al. found that diabetic patients with higher VTV-SBPV had a great risk of developing albuminuria (32) . Jo et al. demonstrated that VTV-SBPV was an independent risk factor for the rapid loss of RRF in PD patients (16) . Mancia et al. suggest that BP variability is a more critical determinant of glomerular damage than the BP level (33).
Our study found that patients with higher BP variability showed a higher IVSDT, LVPWDT, LVMI, and a higher prevalence of LVH. It was consistent with Atas et al. 's reports (15) . We also investigated the changes in PWV, a parameter that reflects arterial stiffness, which plays a cushioning role on BP. We found that PWV was significantly increased in the HBPV group. Thus, we speculated that PWV may be involved in the pathogenesis of the effect of BP and BP variability on RRF and cardiovascular outcome.
It was thought that different antihypertensive medication may have different effects on RRF. In Jo et al. 's study, more calcium channel blockers and diuretics were prescribed in patients with higher VTV-SBPV (16) . A recent meta-analysis of randomized clinical trials showed that the interblood pressure variability was higher with the use of ACEI/ARBs and beta-blockers, and lower with the use of calcium channel blockers (34) . However, there was no significant difference in antihypertensive medication between the two groups in our study, similar to the observation reported by Chang et al. (9) . The effect of antihypertensive drugs on BP variability and RRF needs further study. Some weaknesses of the present study should also be discussed. Firstly, as the study is observational and retrospective in nature, cause and effect cannot be separated. Secondly, the present study involved a relatively small number of patients; further prospective study in a larger dialysis population is needed. Thirdly, baseline data on echocardiography and arterial stiffness were in absence in our study. In addition, we attempted to describe the use of antihypertensive medication clearly; however, the longterm effects of administered drugs cannot be accurately gauged.
In summary, our study suggests that BP variability may affect RRF in PD patients. PD patients with higher BP variability showed a decrease in RRF and a higher LVH and PWV. Decreasing BP variability may help prevent the loss of RRF in PD patients and needs further studies.
